FDA Nominee Gottlieb's Recusals Span Clinical Decision Software Firms, Imaging Centers, Drug Makers
Executive Summary
FDA Commissioner nominee Scott Gottlieb's many pledges to the US Office of Government Ethics to recuse himself from decisions he might make while serving as head of the agency, cover over 35 outfits that he has worked for, is working for, or has invested in, spanning all types of medical commodities, from advanced imaging centers, to drug firms, to clinical decision software specialists and trial designers.
You may also be interested in...
With Gottlieb Sworn In, His Focus Should Be On Quick User-Fee Passage, Industry Advocates Say
Scott Gottlieb was sworn in as US FDA commissioner May 11. Device-industry lobbyists say championing quick passage of user-fee reauthorization should be his near-term priority. Gottlieb is a well-known figure by some in industry, including AdvaMed chief Scott Whitaker, who served with him at HHS during the George W. Bush Administration.
Gottlieb Becomes FDA Commissioner With Immediate Issues Pending
Confirmation comes with fewest votes of any recent commissioner as FDA dealing with budget, user fees and other issues.
Gottlieb Wants Timely Approval Of User Fee Bill, Balanced LDT Plan
FDA Commissioner-nominee Scott Gottlieb was approved by the Senate HELP committee April 27, sending his confirmation to the full Senate. Written responses from Gottlieb to senators' questions provided in advance of the vote don't hold any big surprises, but they provide a view into priorities of the incoming official and the lawmakers, including quick user-fee reauthorization, resolving the lab-developed test oversight debate, off-label and "right-to-try" issues and post-market surveillance.